3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Rectal Neoplasms
4
Glioblastoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Radiation Injuries
2
Prostatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Invasive Breast Cancer
2
Head and Neck Neoplasms
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stomach Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Respiratory Aspiration
1
Prostate Adenocarcinoma
1
Premenopausal Breast Cancer
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
Paclitaxel
6
durvalumab
5
Pemetrexed
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Nivolumab
3
Gemcitabine
3
Docetaxel
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Immunoglobulin G
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trifluridine tipiracil drug combination
1
tremelimumab
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
Surgical Procedures, Operative
×
Clear all
NCT03800134
2025-06-11
AEGEAN
AstraZeneca
Phase 3
Active not recruiting
825 enrolled
1 FDA